<code id='17592EE0B3'></code><style id='17592EE0B3'></style>
    • <acronym id='17592EE0B3'></acronym>
      <center id='17592EE0B3'><center id='17592EE0B3'><tfoot id='17592EE0B3'></tfoot></center><abbr id='17592EE0B3'><dir id='17592EE0B3'><tfoot id='17592EE0B3'></tfoot><noframes id='17592EE0B3'>

    • <optgroup id='17592EE0B3'><strike id='17592EE0B3'><sup id='17592EE0B3'></sup></strike><code id='17592EE0B3'></code></optgroup>
        1. <b id='17592EE0B3'><label id='17592EE0B3'><select id='17592EE0B3'><dt id='17592EE0B3'><span id='17592EE0B3'></span></dt></select></label></b><u id='17592EE0B3'></u>
          <i id='17592EE0B3'><strike id='17592EE0B3'><tt id='17592EE0B3'><pre id='17592EE0B3'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:9589
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Stanford president faces new allegations over 1999 paper
          Stanford president faces new allegations over 1999 paper

          Stanfordisinvestigationallegationsofresearchmisconductagainstitspresident,MarcTessier-Lavigne.AdamFa

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          Merck to acquire Harpoon Therapeutics for $680 million

          MelEvans/APMerckannouncedMondayitwillacquireHarpoonTherapeuticsanditspipelineofimmune-basedcancerdru